Novel Advances in Modifying BMPR2 Signaling in PAH

Area of Science:

• Cardiovascular Medicine
• Pulmonary Hypertension Research
• Molecular Biology

Background:

• Pulmonary Arterial Hypertension (PAH) involves progressive pulmonary artery narrowing, leading to right heart failure and death.
• Current PAH treatments focus on vasodilation but do not prevent vascular remodeling, resulting in high mortality.
• Bone Morphogenetic Protein Receptor 2 (BMPR2) pathway dysfunction is a key factor in PAH pathogenesis.

Purpose of the Study:

• To review existing and novel therapeutic strategies for PAH.
• To explore approaches targeting the BMPR2 signaling pathway for PAH treatment.
• To highlight methods aimed at restoring BMPR2 function and its downstream signaling.

Main Methods:

• Literature review of current and emerging PAH therapies.
• Analysis of studies investigating BMPR2 signaling in PAH.
• Summary of pharmaceutical and genetic strategies to modulate BMPR2.

Main Results:

• Loss-of-function BMPR2 mutations are common in hereditary PAH.
• BMPR2 pathway dysfunction mirrors cellular abnormalities in PAH and experimental PH.
• Restoring BMPR2 signaling shows potential in preclinical models and patient-derived cells.

Conclusions:

• Targeting BMPR2 signaling represents a novel therapeutic avenue for PAH.
• Strategies include increasing BMPR2 expression, enhancing receptor availability, or reconstituting downstream signaling.
• Activating BMPR2 offers a potential to halt or reverse vascular remodeling in PAH.